SCIENTIFIC REFERENCES

  • Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW: Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr 2:pky062, 2018

  • Seah DS, Lin NU, Curley C, Weiner EP, Partridge AH: Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis. J Community Support Oncol 12:347-54, 2014

  • Reed E, Simmonds P, Haviland J, Corner J: Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 43:747-58, 2012

  • Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM, Sperner-Unterweger B, Holzner B: Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128:553-61, 2011

  • Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D: Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624-32, 2009

  • Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D: Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol 34:557-65, 2016

  • Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D: Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA, 2017

  • Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Jr., Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, Covid, Cancer C: Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, 2020

  • Lee LYW, Cazier JB, Starkey T, Turnbull CD, Team UKCCMP, Kerr R, Middleton G: COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet, 2020

  • Sheng JY, Santa-Maria CA, Mangini N, Norman H, Couzi R, Nunes R, Wilkinson M, Visvanathan K, Connolly RM, Roussos Torres ET, Fetting JH, Armstrong DK, Tao JJ, Jacobs L, Wright JL, Thorner ED, Hodgon C, Horn S, Wolff AC, Stearns V, Smith KL: Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract:OP2000364, 2020

  • Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M: Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev 26:809-815, 2017

  • Nachar VR, Farris K, Beekman K, Griggs J, Hough S, Mackler E: Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM). JCO Clin Cancer Inform 3:1-6, 2019

  • Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, Simoni JM, Wilson IB, Saag MS, Kitahata MM, Crane HM: Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav 17:307-18, 2013

  • Hahn EA, Segawa E, Kaiser K, Cella D, Smith BD: Health-related quality of life among women with ductal carcinoma in situ or early invasive breast cancer: validation of the FACT-B (version 4). Expert Review of Quality of Life in Cancer Care 1:99-109, 2016

  • Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-86, 1997

  • Shin JA, El-Jawahri A, Parkes A, Schleicher SM, Knight HP, Temel JS: Quality of Life, Mood, and Prognostic Understanding in Patients with Metastatic Breast Cancer. J Palliat Med 19:863-9, 2016

  • Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC: A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 57:898-910, 2004

  • Hui D, Bruera E: The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments. J Pain Symptom Manage 53:630-643, 2017

  • Basch E, Barbera L, Kerrigan CL, Velikova G: Implementation of Patient-Reported Outcomes in Routine Medical Care. Am Soc Clin Oncol Educ Book 38:122-134, 2018

  • Flannery M, Phillips SM, Lyons CA: Examining telephone calls in ambulatory oncology. J Oncol Pract 5:57-60, 2009

  • Facebook
  • Twitter
  • LinkedIn
  • Vimeo
  • Instagram
  • YouTube
download-on-the-app-store.png
google-play-badge.png

     SCIENCE     BLOG     MEDIA KIT     FAQ     PRIVACY & EULA